21
2016.09
ACTL-targeted anti-tumor cell immunotherapy combined with TKI in the treatment of advanced EGFR-sensitive mutation-positive non-small cell lung cancer: a randomized open, parallel controlled, multicen
Clinical trial contact number: 68217221/68136714/68136396/68136043/68217102 standard constrain 1. T...
